Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
Author(s): PierFranco Conte, MD, PhD1,2; Giancarlo Bisagni, MD3; Federico Piacentini, MD, PhD4; Samanta Sarti, MD, PhD5; Santino Minichillo, MD6; Elisa Anselmi, MD7; Michele Aieta, MD8; Vittorio Gebbia, MD9; Alessio Schirone, MD10; Antonino Musolino, MD, PhD11; Ornella Garrone, MD, PhD12; Alessandra Beano, MD13; Anita Rimanti, MD14; Francesco Giotta, MD15; Anna Turletti, MD16; Federica Miglietta, MD17,18; Maria Vittoria Dieci, MD17,18; Roberto Vicini, PhD19; Sara Balduzzi, MD20; Robert D’Amico, PhD4; and Valentina Guarneri, MD, PhD17,18
Source: DOI: 10.1200/JCO.23.00790 Journal of Clinical Oncology 41, no. 32 (November 10, 2023) 4976-4981.
Dr. Anjan Patel's Thoughts
This is a 10-year follow-up of the ShortHER study using nine weeks vs. 12 months of adjuvant trastuzumab in HR+ non-metastatic breast cancer. With long-term follow-up, non-inferiority could not be claimed statistically. Still, the DFS/OS results are identical in those patients with N0-N3 disease, while those with N4 disease seemed to have a significant difference favoring 12 months of therapy, suggesting that volume/burden of disease drives the margin of benefit in adjuvant trastuzumab therapy.
We present the final analysis of the phase III noninferiority, randomized ShortHER trial comparing 9 weeks versus 1 year of adjuvant trastuzumab with chemotherapy in patients with human epidermal growth factor receptor 2–positive (HER2+) early breast cancer (BC). Women with HER2+ BC were randomly assigned to anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or 9-week trastuzumab (arm B, short). Here, we report the second coprimary end point overall survival (OS), updated disease-free survival (DFS), and outcomes according to hormone receptor status, age, and nodal status. At a median follow-up of 9 years, 10-year DFS is 77% versus 78% in the long versus short arm, respectively. Ten-year OS is 89% versus 88% in the long versus short arm, respectively. 10-year DFS rates in the long versus short arm according to nodal status are N0 81% versus 85%; N1-3 77% versus 79%; and N4+ 63% versus 53%. Ten-year OS rates in long versus short arm according to nodal status are N0 89% versus 95%%; N1-3 92% versus 89%; and N4+ 84% versus 64%. The updated analysis of the ShortHER trial shows that 1-year trastuzumab is the standard treatment for patients with HER2+ early BC as noninferiority cannot be claimed. However, numerically, the differences for the patients at low or intermediate risk (N0/N1-3) is negligible, while patients with N4+ have a clear benefit with 1-year trastuzumab.
Author Affiliations
1S Camillo Hospital, IRCCS, Venezia, Italy; 2University of Padova, Padova, Italy; 3Department of Oncology and Advanced Technologies, Azienda USL-IRCCS, Reggio Emilia, Italy; 4Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy; 5IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori,” IRST srl, Meldola, Italy; 6Medical Oncology, Bellaria Hospital, Bologna, Italy; 7Department of Oncology and Hematology, ASL Piacenza, Piacenza, Italy; 8Medical Oncology, IRCCS-CROB, Rionero in Vulture, Italy; 9Kore University, Enna and La Maddalena Clinic, Palermo, Italy; 10S Anna University Hospital, Ferrara, Italy; 11University Hospital, Parma, Italy; 12IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Breast Oncology, Città della Salute e della Scienza, Torino, Italy; 14Carlo Poma Hospital, ASST Mantova, Mantova, Italy; 15IRCCS Istituto Oncologico Giovanni Paolo II, Bari, Italy; 16Senology, Ospedale Martini, ASL Città di Torino, Torino, Italy; 17Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; 18Oncology 2, Veneto Oncology Institute, IOV-IRCCS, Padova, Italy; 19Statistical Unit, University Hospital, Modena, Italy; 20University of Modena and Reggio Emilia, Modena, ItalyRelated Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
